Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 27, 2025 08:30 ET | Source: SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross Proceeds

NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of...
October 22, 2025 08:00 ET | Source: Calidi Biotherapeutics, Inc

Calidi Biotherapeutics Announces Establishment of Scientific Advisory Board to Support Development of CLD-401 and Advance its RedTail Platform for the Systemic Delivery of Targeted Genetic Medicine

SAN DIEGO, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of...
October 06, 2025 04:54 ET | Source: Research and Markets

Semiconductor Market Analysis 2025: Node Sizes, Types, and Applications in Focus

Dublin, Oct. 06, 2025 (GLOBE NEWSWIRE) -- The "Semiconductor Chips: Applications and Impact of Shortage " report has been added to ResearchAndMarkets.com's offering. The report analyzes the...
September 30, 2025 06:50 ET | Source: Research and Markets

AI Industrial Microcontrollers Market Trends, Competition and Growth Outlook 2025-2030: Decentralized Intelligence in Automation Drives Efficiency

Dublin, Sept. 30, 2025 (GLOBE NEWSWIRE) -- The "AI Industrial Microcontroller Market - Global Forecast 2025-2030" has been added to ResearchAndMarkets.com's offering. The convergence of...
September 24, 2025 07:30 ET | Source: Biogen Inc.

LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Australia

TOKYO and CAMBRIDGE, Mass., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge,...
September 23, 2025 11:00 ET | Source: Innovate GBM

Innovate GBM’s 2025 Investment Playbook Year to Date Review: Building a New Market for Brain Cancer Investments and Breakthroughs

Innovate GBM’s 2025 Impact Report highlights $170M in funding commitments, uniting the Community to grow an Ecosystem of innovation and progress.
September 19, 2025 04:03 ET | Source: Research and Markets

Dual In-line Memory Module (DIMM) Trend Analysis and Forecast Report 2025-2034: Market Set for Growth as DDR5 Powers AI, Cloud, and 5G Advancements

Dublin, Sept. 19, 2025 (GLOBE NEWSWIRE) -- The "Dual In-line Memory Module (DIMM) Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034" report has been added to ...
September 11, 2025 08:30 ET | Source: SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $23.6 Million in Gross Proceeds

NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of...
August 29, 2025 17:00 ET | Source: Biogen Inc.

FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease

LEQEMBI IQLIK is the first and only anti-amyloid treatment to offer an at-home injection to help patients and care partners continue to treat this progressive, relentless disease after initial...
August 25, 2025 03:00 ET | Source: Biogen Inc.

Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab)

TOKYO and CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge,...